Substantial progress has been made over the past four decades in treating the symptoms of Parkinson disease, but treatments that slow its inexorable progression have remained tantalizingly out of reach. New research raises hopes that a means might have been found to safely and effectively slow progression of Parkinson disease and delay its clinical emergence.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Blockade of microglial Cav1.2 Ca2+ channel exacerbates the symptoms in a Parkinson’s disease model
Scientific Reports Open Access 24 June 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Olanow, W. C. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278 (2009).
Wider, C. & Wszolek, Z. K. Clinical genetics of Parkinson's disease and related disorders. Parkinsonism Relat. Disord. 13 (Suppl. 3), S229–S232 (2007).
Tanner, C. M. et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch. Neurol. 66, 1106–1113 (2009).
DeCuypere, M., Lu, Y., Miller, D. D. & LeDoux, M. S. Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. J. Neurochem. 107, 1398–1413 (2008).
Olanow, W. C. & Prusiner, S. B. Is Parkinson's disease a prion disorder? Proc. Natl Acad. Sci. USA 106, 12571–12572 (2009).
Jang, H. et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl Acad. Sci. USA 106, 14063–14068 (2009).
Ritz, B. et al. L-type calcium channel blockers and Parkinson's disease in Denmark. Ann. Neurol. doi: 10.1002/ana.21937.
Surmeier, D. J., Guzman, J. N. & Sanchez-Padilla, J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium doi: 10.1016/j.ceca.2009.12.003.
Guzman, J. N., Sanchez-Padilla, J., Chan, C. S. & Surmeier, D. J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29, 11011–11019 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R. F. Pfeiffer has received honoraria from Boehringer-Ingelheim, GlaxoSmithKline, Novartis and Teva for lectures and honoraria from Boehringer-Ingelheim, Genactis, Ipsen, Kyowa, Schlesinger Associates, Solvay and Theravance for consulting. He has also received research funding from Boehringer-Ingelheim, Eisai, Kyowa, Novartis, Santhera and Schwarz and honoraria from the Michael J Fox Foundation, Northwestern University and the Parkinson Study Group for acting as a clinical trial site investigator.
Rights and permissions
About this article
Cite this article
Pfeiffer, R. Calcium channel blockers and Parkinson disease. Nat Rev Neurol 6, 188–189 (2010). https://doi.org/10.1038/nrneurol.2010.31
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.31
This article is cited by
-
Blockade of microglial Cav1.2 Ca2+ channel exacerbates the symptoms in a Parkinson’s disease model
Scientific Reports (2019)
